SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (772)12/30/2005 11:18:07 AM
From: tom pope  Respond to of 897
 
You do him an injustice. He qualified the "going to zero" with "or much lower". There's a difference.



To: scaram(o)uche who wrote (772)1/2/2006 12:34:44 PM
From: I_Banker  Read Replies (1) | Respond to of 897
 
How does a company with no drugs in late stage trials justify a market cap of $450 million? There are companies with much higher quality pipelines or shipping drugs that have lower market caps. BCRX is up on hype about a drug that was shelved years ago.

Even if their anti-viral was successful, how much patent protection would they still have on it after the approval process was completed?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News